Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

S A Schey, P Fields, J B Bartlett, I A Clarke, G Ashan, R D Knight, M Streetly, A G Dalgleish

    Research output: Contribution to journalArticle

    277 Citations (Scopus)

    Abstract

    To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma.
    Original languageEnglish
    Pages (from-to)3269-76
    Number of pages8
    JournalJournal of Clinical Oncology
    Volume22
    Issue number16
    DOIs
    Publication statusPublished - 2004

    Fingerprint

    Thalidomide
    Multiple Myeloma
    Safety
    pomalidomide

    Cite this

    Schey, S. A., Fields, P., Bartlett, J. B., Clarke, I. A., Ashan, G., Knight, R. D., ... Dalgleish, A. G. (2004). Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. Journal of Clinical Oncology, 22(16), 3269-76. https://doi.org/10.1200/JCO.2004.10.052

    Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. / Schey, S A; Fields, P; Bartlett, J B; Clarke, I A; Ashan, G; Knight, R D; Streetly, M; Dalgleish, A G.

    In: Journal of Clinical Oncology, Vol. 22, No. 16, 2004, p. 3269-76.

    Research output: Contribution to journalArticle

    Schey, SA, Fields, P, Bartlett, JB, Clarke, IA, Ashan, G, Knight, RD, Streetly, M & Dalgleish, AG 2004, 'Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma', Journal of Clinical Oncology, vol. 22, no. 16, pp. 3269-76. https://doi.org/10.1200/JCO.2004.10.052
    Schey, S A ; Fields, P ; Bartlett, J B ; Clarke, I A ; Ashan, G ; Knight, R D ; Streetly, M ; Dalgleish, A G. / Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 16. pp. 3269-76.
    @article{d308a3d30b7e45f99d7ac990d8edf014,
    title = "Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma",
    abstract = "To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma.",
    author = "Schey, {S A} and P Fields and Bartlett, {J B} and Clarke, {I A} and G Ashan and Knight, {R D} and M Streetly and Dalgleish, {A G}",
    year = "2004",
    doi = "10.1200/JCO.2004.10.052",
    language = "English",
    volume = "22",
    pages = "3269--76",
    journal = "Journal of Clinical Oncology",
    issn = "0732-183X",
    publisher = "American Society of Clinical Oncology",
    number = "16",

    }

    TY - JOUR

    T1 - Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

    AU - Schey, S A

    AU - Fields, P

    AU - Bartlett, J B

    AU - Clarke, I A

    AU - Ashan, G

    AU - Knight, R D

    AU - Streetly, M

    AU - Dalgleish, A G

    PY - 2004

    Y1 - 2004

    N2 - To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma.

    AB - To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma.

    U2 - 10.1200/JCO.2004.10.052

    DO - 10.1200/JCO.2004.10.052

    M3 - Article

    C2 - 15249589

    VL - 22

    SP - 3269

    EP - 3276

    JO - Journal of Clinical Oncology

    JF - Journal of Clinical Oncology

    SN - 0732-183X

    IS - 16

    ER -